Status:
RECRUITING
: Vascular Function in Health and Disease
Lead Sponsor:
Russell Richardson
Conditions:
Chronic Obstructive Pulmonary Disease
Pulmonary Artery Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Many control mechanisms exist which successfully match the supply of blood with the metabolic demand of various tissues under wide-ranging conditions. One primary regulator of vasomotion and thus perf...
Detailed Description
Angiotensin-II (ANG-II) is the end-product of the renin-angiotensin cascade, and acts as a potent endogenous vasoconstrictor through binding to the angiotensin receptor (AT1) on arteriolar vascular sm...
Eligibility Criteria
Inclusion Criteria:
- Healthy Young Volunteers: 18-30 years of age with no diseases or conditions that would affect their participation in the study
- Healthy Older Controls: volunteers 65 years of age or older with no diseases or conditions that would affect their participation in the study
- Coronary Angiography subjects: patients undergoing routine coronary angiography
- Chronic Obstructive Pulmonary Disease subjects: patients diagnosed with mild to moderate COPD
- Pulmonary Arterial Hypertension subjects: patients with idiopathic or heritable Group 1 pulmonary arterial hypertension
- Heart Failure subjects: patients with Class I, II or III New York Heart Association symptoms of Heart Failure
- Hypertension subjects: patients diagnosed with chronic high blood pressure
Exclusion Criteria:
- Severe COPD (use of supplemental oxygen, or have a one-second forced expiratory volume of less than 30% predicted)
- History of myocardial infarction
- History of percutaneous coronary revascularization
- History of coronary artery bypass grafting
- Unstable angina pectoris
- History of variant angina
- Ejection fraction < 50%
- Significant renal disease (Glomerular Filtration Rate < 50 mL/min/1.73m2)
- Subjects whose medical care or safety may be at risk from undergoing a Magnetic Resonance Imaging examination (e.g. pacemaker, metal implants, certain types of heart valves)
- Subject is pregnant
- Subject has physical ailments (other than COPD, PAH, HF, or hypertension) that would prevent them from study participation in the judgment of the investigator
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
420 Patients enrolled
Trial Details
Trial ID
NCT02966665
Start Date
September 1 2008
End Date
August 1 2026
Last Update
September 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
George E Wahlen VA Medical Center
Salt Lake City, Utah, United States, 84132